Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy | Zendy

Ana Jiménez Ubieto | Zendy; Carlos Grande | Zendy; Dolores Caballero | Zendy; Lucrecia Yáñez | Zendy; Silvaovelli | Zendy; Miguel Teodoro HernándezGarcia | Zendy; María Manzanares | Zendy; Reyes Arranz | Zendy; José Luis Ferreiro | Zendy; Sabela Bobillo | Zendy; Santiago Mercadal | Zendy; Andrea Galeo | Zendy; Javier López Jiménez | Zendy; José M. Moraleda | Zendy; Carlos Vallejo | Zendy; Carmen Albó | Zendy; Elena Pérez | Zendy; Carmen Marrero | Zendy; Laura Magnano | Zendy; Luis Palomera | Zendy; Isidro Jarque | Zendy; Antonia Rodríguez | Zendy; Leyre Lorza | Zendy; Alejandro Martı́n | Zendy; Erika Coria | Zendy; Armando LópezGuillermo | Zendy; Antonio Salar | Zendy; Juan José Lahuerta | Zendy

Open Access

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy

Author(s) -

Ana Jiménez Ubieto,

Carlos Grande,

Dolores Caballero,

Lucrecia Yáñez,

Silvaovelli,

Miguel Teodoro HernándezGarcia,

María Manzanares,

Reyes Arranz,

José Luis Ferreiro,

Sabela Bobillo,

Santiago Mercadal,

Andrea Galeo,

Javier López Jiménez,

José M. Moraleda,

Carlos Vallejo,

Carmen Albó,

Elena Pérez,

Carmen Marrero,

Laura Magnano,

Luis Palomera,

Isidro Jarque,

Antonia Rodríguez,

Leyre Lorza,

Alejandro Martı́n,

Erika Coria,

Armando LópezGuillermo,

Antonio Salar,

Juan José Lahuerta

Publication year - 2019

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2019.06.001

Subject(s) - medicine , rituximab , autologous stem cell transplantation , cohort , oncology , follicular lymphoma , chemotherapy , lymphoma , overall survival , progression free survival , surgery

Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT. We explored whether ASCT is also an effective option in the pre-rituximab era-that is, in patients treated in induction and rescued only with chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research